These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31350854)

  • 1. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.
    Ferraro D; Guicciardi C; De Biasi S; Pinti M; Bedin R; Camera V; Vitetta F; Nasi M; Meletti S; Sola P
    Acta Neurol Scand; 2020 Jan; 141(1):16-21. PubMed ID: 31350854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis.
    Emeršič A; Karikari TK; Kac PR; Gonzalez-Ortiz F; Dulewicz M; Ashton NJ; Brecl Jakob G; Horvat Ledinek A; Hanrieder J; Zetterberg H; Rot U; Čučnik S; Blennow K
    Mult Scler Relat Disord; 2024 Oct; 90():105801. PubMed ID: 39153429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.
    Guimarães I; Cardoso MI; Sá MJ
    Mult Scler; 2006 Jun; 12(3):354-6. PubMed ID: 16764350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
    Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
    Eur Neurol; 2024; 87(4):203-210. PubMed ID: 38754397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilaments and 10-year follow-up in multiple sclerosis.
    Bhan A; Jacobsen C; Myhr KM; Dalen I; Lode K; Farbu E
    Mult Scler; 2018 Sep; 24(10):1301-1307. PubMed ID: 30066611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
    Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
    Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I
    Neurology; 2020 Jun; 94(23):e2457-e2467. PubMed ID: 32434867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
    Eikelenboom MJ; Petzold A; Lazeron RH; Silber E; Sharief M; Thompson EJ; Barkhof F; Giovannoni G; Polman CH; Uitdehaag BM
    Neurology; 2003 Jan; 60(2):219-23. PubMed ID: 12552034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
    Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
    Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.